Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.42 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.42 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.42 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22159822 | 0.89 | DPP4 (0.53) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL729512 | 0.79 | PDE3B (0.69) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 | |
| SCHEMBL29061677 | 0.78 | LMNA (0.57) | CYP1A2LMNACAMKK1CAMKK2 | |
| SCHEMBL22119789 | 0.78 | LMNA (0.57) | CYP1A2LMNACAMKK1CAMKK2 | |
| SCHEMBL30592742 | 0.78 | LMNA (0.57) | CYP1A2LMNACAMKK1CAMKK2 | |
| SCHEMBL22120025 | 0.77 | GSK3B (0.52) | LMNACAMKK1CAMKK2TDP2GSK3B | |
| SCHEMBL22120030 | 0.76 | PIK3CA (0.57) | MELKLMNACAMKK1CAMKK2 | |
| SCHEMBL22120075 | 0.75 | PARP11 (0.55) | LMNADPP4CAMKK1CAMKK2GSK3B | |
| SCHEMBL22119874 | 0.75 | MAPKAPK2 (0.60) | LMNACAMKK1CAMKK2 | |
| SCHEMBL22159987 | 0.75 | TBXAS1 (0.47) | PDE3BPDE3ACYP1A2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-11504364-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2022-11-22 | — | — | US | disclosed |
| CN-113811529-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2021-12-17 | — | — | CN | disclosed |
| EP-3898654-A2 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20200206216-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2020-07-02 | — | — | US | disclosed |
| WO-2020132661-A2 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | PDE3B 1363/4885PDE3A 1160/4885CYP1A2 4573/4885 |
| US-11504364-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | PDE3B 1363/4885PDE3A 1160/4885CYP1A2 4573/4885 |
| US-20200206216-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | PDE3B 1363/4885PDE3A 1160/4885CYP1A2 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.